Today’s company is helping the medical industry fight COVID-19…
According to the New York Times, the seven-day average of daily COVID-19 deaths in the U.S. surpassed 2,000 last weekend. That’s a high we haven’t seen since March. And as the Delta variant continues to drive up cases around the world, it’s clear the pandemic is far from over. So today, we’re checking in on a major player in COVID-19 vaccine development…
Repligen (RGEN) is a $20 billion leader in life sciences. When we last highlighted the company, it was helping to purify COVID-19 vaccines. Since then, Repligen has launched its own affinity resin to be used in the purification process… And it’s continuing to put its innovations to good use in this difficult time. COVID-19-related sales made up 27% of Repligen’s revenue in the most recent quarter, while total revenues – including its base business – grew 69% year over year to $163 million.
As you can see, RGEN is up more than 120% over the past year. It also recently hit a fresh all-time high. And as Repligen continues to aid in the fight against COVID-19, we can expect this uptrend to continue…
Marc Chaikin warned people about NVDA before its 2023 bull run - now he's naming his next pick or the AI tidal wave. Learn more here.
Source: Daily Wealth’s Market Notes